Glycotest is a liver disease diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis.  Founded in 2012 by NetScientific plc on technology originating at the Baruch S. Blumberg Institute and Drexel University College of Medicine, we have exclusive, world-wide rights to over 50 patent-protected serum glycoprotein biomarkers that exploit novel sugar-based disease signals.  The Company’s lead test for curable early-stage liver cancer has significantly outperformed the current standard blood test in multiple preliminary clinical studies.  Our mission is to revolutionize the care and treatment of the at-risk chronic liver disease population, including the rapidly growing population with NASH.

Glycotest was created in 2012 based on technology developed by two experts in the fields of liver disease and glycobiology-Professors Timothy Block and Anand Mehta at Drexel University College of Medicine and the Baruch S. Blumberg Institute. Glycotest has the exclusive worldwide rights to the use of over 50 patented serum glycoprotein biomarkers whose sugar structures are altered in liver cancers and fibrosis-cirrhosis by the abnormal attachment of the monosaccharide fucose.

Our first test is the HCC Panel which is designed for the early detection of Hepatocellular Carcinoma (HCC). The HCC Panel is a surveillance test for patients who have had chronic liver disease and are at a higher risk of getting HCC. If HCC is detected early, it can be curable, but unfortunately, current test methods are not sensitive enough to catch most early-stage HCC. The HCC Panel test is currently being used in a 476 patient clinical validation study which we expect will be completed in mid-2020. We are planning to launch the HCC Panel to hepatologists late next year through our CLIA lab.